Everest Organics Ltd.

Financial

	Everest Organics	Bal Pharma	Tyche Inds
Operational Metrics
API Sector
Manufacturing Capacity - Esomeprazole	144.0 MTPA	n/a	n/a
Capacity Utilization - Esomeprazole	65.56 %	n/a	n/a
Capacity Utilization - Benzimidazole	87.52 %	n/a	n/a
Capacity Utilization - Omeprazole	85.77 %	n/a	n/a
Realization - Pantaprazole Sodium	4015482.23 Rs/Tonne	n/a	n/a
Realization - Ammonium Sulphate	22104.75 Rs/Tonne	n/a	n/a
Realization - Esomeprazole Magnesium	3625281.87 Rs/Tonne	n/a	n/a
Realization - Chloro Compound	2039819.1 Rs/Tonne	n/a	n/a
Manufacturing Capacity - Pantaprazole	60.0 MTPA	n/a	n/a
Realization - Omeprazole Powder	2963407.74 Rs/Tonne	n/a	n/a
Manufacturing Capacity - Benzimidazole	250.0 MTPA	n/a	n/a
Capacity Utilization - Chloro Compound	70.95 %	n/a	n/a
Realization - Benzimidazole	1270727.38 Rs/Tonne	n/a	n/a
Realization - Op. Sulphide	2949666.67 Rs/Tonne	n/a	n/a
Capacity Utilization - Pantaprazole	13.43 %	n/a	n/a
Manufacturing Capacity - Chloro Compound	480.0 MTPA	n/a	n/a
Realization - Tetralone	700000.0 Rs/Tonne	n/a	n/a
Manufacturing Capacity - Omeprazole	215.0 MTPA	n/a	n/a
Pharmaceutical Sector
R&D as a % of Total Sales	1.13 %	0.88 %	1.3 %
Financials
5 yr Average ROE	12.73 %	1.96 %	14.86 %
5yr average Equity Multiplier	3.91	4.59	1.18
5yr Average Asset Turnover Ratio	1.13	0.98	0.6
5yr Avg Net Profit Margin	2.92 %	-0.04 %	20.15 %
Price to Book	7.83	2.51	1.17
P/E	0.0	23.84	11.49
5yr Avg Cash Conversion Cycle	-87.83 Days	41.77 Days	86.71 Days
Inventory Days	61.25 Days	106.16 Days	61.45 Days
Days Receivable	142.15 Days	104.16 Days	108.17 Days
Days Payable	226.8 Days	132.37 Days	93.08 Days
5yr Average Interest Coverage Ratio	3.02	1.22	2385.83
5yr Avg ROCE	19.01 %	15.4 %	19.65 %
5yr Avg Operating Profit Margin	6.68 %	7.79 %	23.57 %
5 yr average Debt to Equity	0.84	2.03	0.0
5yr CAGR Net Profit	-58.15 %	n/a	-6.96 %
5yr Average Return on Assets	3.96 %	0.43 %	12.43 %
Shareholdings
Promoter Holding	61.09 %	50.86 %	61.97 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-13.06 %	1.29 %	0.0
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	0.0

Business

	Everest Organics	Bal Pharma	Tyche Inds
Product Wise Break-Up	Product Wise Break-Up Omeprazole Powder 46.36 Esomeprazole Magnesium 38.94 Pantaprazole Sodium 5.59 Rabeprazole 5.3 Fenofibrate 3.38 Dexlansoprazole 0.43 Oseltamivir 0 Tetralone 0 Ammonium Sulphate 0 Op. Sulphide 0 Chloro Compound 0 Benzimidazole 0 Formulations 0 API 0 Manufacture of bulk drugs intermediates 0	Product Wise Break-Up Tetralone 0 Fenofibrate 0 Dexlansoprazole 0 Benzimidazole 0 Active Pharmaceutical Ingredient (API) 48.19 Esomeprazole Magnesium 0 Omeprazole Powder 0 Pantaprazole Sodium 0 Chloro Compound 0 Oseltamivir 0 Op. Sulphide 0 Manufacture of bulk drugs intermediates 0 Rabeprazole 0 Ammonium Sulphate 0 Formulations 45.98 Others 5.83	Product Wise Break-Up Tetralone 0 Fenofibrate 0 Dexlansoprazole 0 Benzimidazole 0 API 0 Esomeprazole Magnesium 0 Omeprazole Powder 0 Pantaprazole Sodium 0 Chloro Compound 0 Oseltamivir 0 Op. Sulphide 0 Bulk Chemicals 100.0 Rabeprazole 0 Ammonium Sulphate 0 Formulations 0
Segment Break-Up	Segment Break-Up Active Pharmaceutical Ingredient (API) 100.0	-	-
Location Wise Break-Up	Location Wise Break-Up India 73.7 Rest of the World 26.3 International 0 Domestic 0	Location Wise Break-Up International 0 Rest of the World 64.15 India 35.85 Domestic 0	Location Wise Break-Up International 67.08 Rest of the World 0 India 0 Domestic 32.92
Raw Material Break-Up	Raw Material Break-Up 3, 5 Lutidine 40.3 Para Anisidine 13.59 Toluene 12.23 Acetone 11.13 MDC 786.60 7.9 APS 206.88 6.87 Acetic Acid 4.77 DMS 299.44 3.21 Others 0	-	-

Everest Organics Ltd.

SIGN UP FOR FREE